Corbus Pharmaceuticals Q4 2019 Earnings Report
Key Takeaways
Corbus Pharmaceuticals reported revenue of $2.6 million and a net loss of $26.6 million for the fourth quarter ended December 31, 2019. The company's cash and cash equivalents were $31.7 million at the end of the quarter.
Revenue from awards and licenses was $2.6 million for the three months ended December 31, 2019, compared to $1.9 million in the comparable period in 2018.
Operating expenses increased by $10.3 million to $29.8 million for the three months ended December 31, 2019, compared to $19.5 million for the year ago period.
The Company reported a net loss of approximately $26.6 million or a net loss per diluted share of $0.41, for the three months ended December 31, 2019, compared to a net loss of approximately $17.3 million, or a net loss per diluted share of $0.30, for the same period in 2018.
Cash and cash equivalents were $31.7 million at December 31, 2019.